Tsarfaty G, Longo D L, Murphy W J
Laboratory of Leukocyte Biology, National Cancer Institute-Frederick Cancer Research and Development Center, MD 21702-1201.
Exp Hematol. 1994 Dec;22(13):1273-7.
Recombinant human insulin-like growth factor I (rhIGF-I) was administered to mice to determine its effect on hematopoiesis. Mice given intraperitoneal (IP) injections of 5 micrograms rhIGF-I for 7 days exhibited a significant increase in bone marrow (BM) hematopoietic progenitor cells, suggesting that rhIGF-I acts as a hematopoietic growth factor. Treatment with rhIGF-I also resulted in increases in erythroid precursor cells. Mice were then placed on azidothymidine (AZT), which produces significant myelotoxic effects. Splenic and BM progenitor cell content and hematocrit values were all significantly increased if rhIGF-I (5 micrograms injected IP every day for 28 days) was concurrently administered with AZT. Additionally, when mice were initially myelosuppressed by several weeks of AZT treatment, the subsequent administration of rhIGF-I resulted in an increase in hematopoietic progenitor cell content. No significant pathologic effects or weight changes were observed in mice receiving repeated injections of rhIGF-I at this dose and schedule. Thus, rhIGF-I exerts hematopoietic growth-promoting effects in vivo and may be of potential clinical use in promoting hematopoiesis in the face of myelotoxic therapy.
给小鼠注射重组人胰岛素样生长因子I（rhIGF-I）以确定其对造血作用的影响。腹腔注射5微克rhIGF-I、持续7天的小鼠，其骨髓造血祖细胞显著增加，这表明rhIGF-I起到造血生长因子的作用。用rhIGF-I治疗还导致红系前体细胞增加。随后给小鼠使用齐多夫定（AZT），它会产生显著的骨髓毒性作用。如果rhIGF-I（每天腹腔注射5微克、持续28天）与AZT同时给药，脾脏和骨髓祖细胞含量以及血细胞比容值均显著增加。此外，当小鼠最初经数周AZT治疗出现骨髓抑制时，随后给予rhIGF-I会导致造血祖细胞含量增加。按此剂量和给药方案对小鼠反复注射rhIGF-I，未观察到明显的病理效应或体重变化。因此，rhIGF-I在体内发挥促进造血的作用，在面对骨髓毒性治疗时，可能在促进造血方面具有潜在的临床应用价值。
